Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phosphodiesterase and immune dysfunction in atopic dermatitis.

J M Hanifin1

  • 1Department of Dermatology, Oregon Health Sciences University, Portland 97201.

Journal of Dermatological Science
|January 1, 1990
PubMed
Summary

Atopic dermatitis involves immune cells, with leukocyte abnormalities like elevated cyclic AMP-phosphodiesterase contributing to the condition. Targeting this enzyme may offer new therapeutic strategies for atopic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioneers in Dermatology and Venereology: an interview with Jon Hanifin, M.D.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality-of-life measure for adult atopic dermatitis.

The British journal of dermatology·2018
Same author

Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitis.

The British journal of dermatology·2017
Same author

What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.

The British journal of dermatology·2015
Same author

Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2014
Same author

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

The British journal of dermatology·2014

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis and related conditions involve hematopoietic cells.
  • Cellular immune issues in atopic dermatitis appear secondary to skin inflammation.
  • Leukocyte abnormalities, including defective cyclic nucleotide metabolism, are noted.

Purpose of the Study:

  • To investigate leukocyte abnormalities in atopic dermatitis.
  • To explore the role of cyclic AMP-phosphodiesterase in atopic conditions.
  • To assess the potential of phosphodiesterase inhibitors as a therapeutic target.

Main Methods:

  • Examined leukocyte abnormalities in patients with atopic dermatitis.
  • Investigated cyclic AMP-phosphodiesterase activity in leukocytes.

Related Experiment Videos

  • Studied the effects of phosphodiesterase inhibitors on cultured atopic leukocytes.

    • Main Results:

    • A consistent abnormality found in atopic leukocytes is elevated cyclic AMP-phosphodiesterase.
    • This enzyme elevation leads to reduced intracellular cyclic AMP levels.
    • Phosphodiesterase inhibitors decreased abnormal histamine release and IgE production in cultured leukocytes.

    Conclusions:

    • Elevated cyclic AMP-phosphodiesterase in atopic leukocytes is a key abnormality.
    • This defect impacts cell function and may underlie atopic conditions.
    • Targeting phosphodiesterase offers a potential therapeutic avenue for atopic diseases.